AbbVie Quarterly Cash Flow Statement
NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
AbbVie free cash flow
In the quarter ended Jun 30, 2026, AbbVie generated $3.44 billion of operating cash flow and spent $322.0 million on capital expenditures. That left free cash flow of $3.11 billion, a free-cash-flow margin of 18.3% of revenue. Free cash flow was down 36.2% from the prior year's $4.88 billion.
AbbVie returned $3.08 billion to shareholders: $3.07 billion in dividends and $9.0 million in share repurchases, equal to 99% of free cash flow. Free cash flow covered dividend payments 1.0 times.
Summary generated from market data by MetaCap's automated system. Methodology
AbbVie cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 3.62B | 697.00M | 1.81B | 188.00M | 941.00M | 1.29B | -23.00M | 1.56B | 1.37B | 1.37B | 824.00M | 1.78B |
| Net Income growth (YoY) | +284.27% | -45.93% | — | -87.98% | -31.46% | -6.05% | -102.79% | -12.18% | -32.26% | +469.29% | -66.67% | -54.93% |
| Depreciation & Amortization | 194.00M | 188.00M | 203.00M | 192.00M | 186.00M | 181.00M | 206.00M | 191.00M | 184.00M | 183.00M | 187.00M | 196.00M |
| Stock-Based Compensation | 166.00M | 444.00M | 157.00M | 209.00M | 179.00M | 410.00M | 164.00M | 181.00M | 218.00M | 348.00M | 125.00M | 130.00M |
| Change in Working Capital | -498.00M | -1.84B | -1.12B | 1.66B | 813.00M | -2.96B | 1.41B | 699.00M | -1.55B | -131.00M | 32.00M | 2.59B |
| Operating Cash Flow | 3.44B | 3.83B | 5.22B | 7.02B | 5.15B | 1.64B | 7.05B | 5.45B | 2.27B | 4.04B | 4.75B | 7.57B |
| Capital Expenditures | -322.00M | -265.00M | -329.00M | -381.00M | -269.00M | -235.00M | -291.00M | -249.00M | -241.00M | -193.00M | -205.00M | -219.00M |
| Investing Cash Flow | -1.20B | -574.00M | -1.46B | -3.26B | -1.18B | -735.00M | -1.87B | -8.26B | -1.10B | -9.59B | -800.00M | -369.00M |
| Dividends Paid | -3.07B | -3.09B | -2.91B | -2.91B | -2.91B | -2.92B | -2.75B | -2.75B | -2.75B | -2.77B | -2.63B | -2.63B |
| Share Repurchases | -9.00M | -1.49B | -3.00M | -4.00M | -12.00M | -961.00M | -358.00M | -17.00M | -9.00M | -1.32B | -3.00M | -4.00M |
| Debt Issued | 0 | 7.99B | 0 | 0 | 0 | 3.99B | 2.00B | 0 | 0 | 14.96B | — | 0 |
| Debt Repaid | -2.00B | 0 | -8.00M | -9.00M | -3.75B | -3.03B | -5.76B | -403.00M | -3.35B | -103.00M | -1.79B | -2.00M |
| Financing Cash Flow | -5.05B | 919.00M | -4.17B | -4.59B | -2.71B | -1.26B | -6.86B | -3.07B | -6.10B | 10.82B | -4.45B | -2.66B |
| Net Change in Cash | -2.82B | 4.16B | -400.00M | -838.00M | 1.29B | -349.00M | -1.73B | -5.87B | -4.94B | 5.25B | -473.00M | 4.53B |
| Free Cash Flow | 3.11B | 3.56B | 4.89B | 6.64B | 4.88B | 1.40B | 6.76B | 5.20B | 2.03B | 3.85B | 4.55B | 7.36B |
This table shows 12 quarterly periods of AbbVie's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABBV's reporting calendar. What is a cash flow statement?